Journals

Explore novel research, stay current on clinical trials, and find answers to your clinical care questions in case reports.
Covers of JTO CRR and JPO

Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.

JTO CRR in PubMed Central and Web of Science!

JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 20.4, JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews and opinion pieces. JTO CRR, IASLC’s open access companion title, publishes a range of manuscripts from subset analyses of published trials to high-quality case reports. JTO CRR is indexed in PubMed Central and Web of Science.

JTO IF Graphic
Alex Adjei

Editor-in-Chief, JTO on 2022 Impact Factor

Alex A. Adjei, MD, PhD

"JTO’s impact factor has more than quadrupled from 5.040 in 2015 to 20.4 in 2022. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals. More importantly, the impact factor of other journals in thoracic oncology or surgery fell in 2022. This achievement is a testament to the exemplary work of our editorial board and our managing editor, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology.” 

Emily Stone

JTO CRR Editor-in-Chief

Emily Stone, MBBS, PhD, FRACP

Dr. Emily Stone will officially take the reins as the Editor-in-Chief of JTO Clinical and Research Reports (JTO CRR) on January 9, 2023, as Dr. Alex Adjei steps down from the role and continues his role as the Editor-in-Chief of the Journal of Thoracic Oncology (JTO). Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney. She is the founding and immediate past Chair of the St Vincent’s Hospital Lung Cancer Multidisciplinary Team and the Deputy Board Chair of the Thoracic Oncology Group of Australasia. She has been an Associate Editor for both the JTO and JTO CRR since 2016 and 2020, respectively. She also served as the Chair of the IASLC Tobacco Control Committee from 2018 to 2019. Her chief clinical and research interests are in the fields of lung cancer screening, multidisciplinary team care, and tobacco control.   
 

JTO CRR

We are excited for the next chapter under Dr. Stone's editorial leadership and strategic stewardship of JTO CRR. The editorial teams of JTO and JTO CRR are committed to continuing to join forces towards research excellence, impacting clinical practice and global readership. We want to express our utmost appreciation to Dr. Adjei for his leadership and vision in paving the way for JTO CRR. Please join us in welcoming Dr. Stone to the JTO CRR family. 

Most-Cited Journal of Thoracic Oncology Articles in 2022

JTO

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

May 08, 2022

JTO by the Numbers

13
out of 241 in 2021 Oncology Journals
4
out of 65 in 2021 Respiratory Journals
20.4
Impact Factor (up from 20.1 in 2021)
1,704%
increase in 6 years full-text article downloads

Recent journal articles

Discover the JTO

JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:

JTO RSS Feed

JTO articles

Subscribe to receive alerts about new content from JTO 

Searches, Citations, or Collection

Searches, Citations or Collection

Subscribe to receive alerts about saved searches, citations, or collections

Monthly Quick Poll

Journals stock poll

Participate in the monthly Quick Poll

Journal of Thoracic Oncology Impact Factor Continues to Increase

JTO cover 1

The JTO, the official journal of the IASLC, now ranks 13th out of all 241 oncology journals and 4th out of all 65 respiratory system journals.

More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.

JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.

JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to journals@iaslc.org

New JTO Collections

JTO

Statistics in Oncology Series

This collection of articles covers fundamental statistical principles and recommendations for best practice.

JTO

Lung Cancer Worldwide Editorials

These articles offer a synopsis of lung cancer epidemiology, screening, prevention, diagnosis and therapy in different countries all over the world.

Discover the JTO CRR

Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.

JTO CRR RSS Feed